Acronyms that contain the term nexbio 

NexBio

NexBio is a San Diego based company in operation since 2003. NexBio is the recipient of five NIH grants totaling $14M and a BAA contract for $49.5M. NexBio's lead product, Fludase®, is currently undergoing Phase II clinical development. Fludase® is in clinical development as a first-in-class broad-spectrum prophylactic and therapeutic agent for Influenza-Like Illness caused by all annual and pandemic variations of influenza virus (IFV), including Pandemic Influenza A(H1N1) and avian H5N1, as well as parainfluenza. Fludase® is currently undergoing a Phase II clinical trial for the treatment of community acquired influenza. NexBio is performing lead optimization of a second novel protein therapeutic, Sepcidin™. NexBio has also invented TOSAP® a proprietary microparticle formulation technology used for its compounds, as well as those of its partners. Our mission is to save lives and to improve the quality of life by creating and commercializing novel, broad-spectrum biopharmaceuticals to prevent and treat current and emerging life-threatening human diseases.

see more »